FLT3 and acute myeloid leukemia: Fathi et al. [14] observed that cabozantinib was well tolerated in AML patients with FLT3-ITD and effectively inhibited the FLT3-mutated AML, demonstrating the feasibility of cabozantinib for AML treatment.